β2-Glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of β2-glycoprotein I

Thrombosis and Haemostasis

Volumn 86, Issue 2, 2001, Pages 590-595

  McNeeley, P A ^a   Dlott, J S ^a   Furie, R A ^a   Jack, R M ^a   Ortel, T L ^a   Triplett, D A ^a   Victoria, E J ^a   Linnik, M D ^a  

^a La Jolla Pharmaceutical Company   (United States)

Author keywords

Anticardiolipin antibodies; Antiphospholipid syndrome; 2 Glycoprotein I

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; EPITOPE; IMMUNOGLOBULIN G; GLYCOPROTEIN;

AMINO TERMINAL SEQUENCE; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DELETION MUTANT; HUMAN; METHODOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; SURFACE PLASMON RESONANCE; ADULT; CASE CONTROL STUDY; CHEMISTRY; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PROTEIN TERTIARY STRUCTURE;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; CASE-CONTROL STUDIES; COHORT STUDIES; EPITOPES; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROTEIN STRUCTURE, TERTIARY; SURFACE PLASMON RESONANCE;

EID: 0034742562     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616091     Document Type: Article

References (34)

1. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant
2. The antiphospholipid syndrome: Ten years on
3. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: Beta 2-glycoprotein I (apolipoprotein H)
4. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a serum protein cofactor
5. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease
6. Amino acid sequence and location of the disulfide bonds in bovine beta 2 glycoprotein I: The presence of five sushi domains
7. The fifth domain of beta 2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies
8. Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies
9. 2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a baculovirus system
10. Anti-beta 2-glycoprotein I antibody: Specificity and clinical significance
11. 2-GPI recognized by anticardiolipin antibodies
12. 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity
13. 2-glycoprotein 1 fifth-domain antibodies in sera from patients with systemic lupus erythematosus
14. Epitope specificity of monoclonal anti-beta 2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome
15. 2-GPI
16. 2-glycoprotein I antibodies
17. Antiphospholipid antibodies. Annotation
18. Antibody affinities and relative titers in polyclonal populations: Surface plasmon resonance analysis of anti-DNA antibodies
19. Quantitative determination of surface concentration of protein with surface plasmon resonance by using radiolabeled proteins
20. Target recognition of beta2-glycoprotein I (beta2GPI)-dependent anticardiolipin antibodies: Evidence for involvement of the fourth domain of beta2GPI in antibody binding
21. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure
22. Platelet activating properties of murine monoclonal antibodies to beta 2-glycoprotein I
23. Anticardiolipin antibodies block the inhibition by beta 2-glycoprotein I of the factor Xa generating activity of platelets
24. Exposure of anionic phospholipids upon platelet activation permits binding of beta 2 glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects
25. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo
26. Congenital resistance to activated protein C in patients with lupus anticoagulants: Evaluation of two functional assays
27. Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: Beta2-glycoprotein I interferes with binding of protein S to its serum inhibitor, C4b-binding protein
28. Antiphospholipid antibodies accelerate serum coagulation by inhibiting annexin-V binding to phospholipids: A "lupus procoagulant" phenomenon
29. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I
30. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I
31. Monovalent binding of autoantibodies to B2-glycoprotein I, detected using surface plasmon resonance at low antigen density
32. Structural characterization and optimization of antibody-selected phage library mimotopes of an antigen associated with autoimmune recurrent thrombosis
33. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides
34. Multivalent thioether-peptide conjugates: B cell tolerance of an anti-peptide immune response